RE:RE:just think Uddin and Ma pointed to strong sales over the first three quarter of 2020 for MDP’s US business (showing a 76-per-cent year-over-year growth) and its Canadian business (showing 14 per cent growth. The analysts noted that MDP is working on a label expansion for Ixinity in the US, while in Canada it is working toward a full launch of imaging agent Gleolan and looking to receive Health Canada approval in May 2021 for hematopeoietic stem cell transplantation agent Treosulfan.